Advisory Board and Editors Immunology
Julia Kzhyshkowska
1997: PhD Cancer Research Centre of the Russian Academy of Medical Sciences, Moscow.
1997-2001: Postdoc at the University of Regensburg
2001-2007: Junior group leader/PI and lecturer, University of Heidelberg.
2007- 2010:Senior group leader/PI and senior lecturer, University of Heidelberg
2010-2013: Professor, head of the Lab for Cellular and Molecular Biology of Innate Immunity;
2013-permanent: Professor, head of Department for Innate Immunity and Tolerance, University of Heidelberg.
Ning Li
Prof. Li received his Medical Doctorate in 2005 as an outstanding graduate of the Chinese Union Medical University (CUMU). In the same year, he worked in the Department of Thoracic Surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences, where he served as an attending physician, deputy chief physician, and was appointed Chief Physician in 2019. He has a solid theoretical foundation and excellent research ability, and has accumulated rich clinical experience during my work. In 2017, he took over as the Director of the Office of Drug Clinical Trial Research Center, and his outstanding achievements in the management of clinical trial institutions and clinical and translational research, and is currently served as the chief expert of China GCP platform and Leading PI of international multicenter clinical trials of anti-cancer drug discovery. He is committed to new anti-tumor drug research, real-world research, full chain translation research of clinical trials, precision treatment of rare tumors and tumor big data research. His H-Index is 44 based on Web of Science. As a sub-project leader of the National 973 Major Project, the National Key R&D Program for Precision Medicine, the National Natural Science Foundation of China, the GCP platform leader, and the leader of the 13th and 14th Five-Year Innovation Project, he has undertaken many research projects.
Dongliang Liu
Dr. Dongliang Liu is a Postdoctoral Associate in the Department of Surgery at the Baylor College of Medicine. His research interests include: Cancer therapy, especially for pancreatic cancer immunotherapy; Chimeric virus-like particles (VLP) vaccine, especially for cancer vaccines; Novel antibiotics development including antimicrobial peptides; Epitomics and multi-epitope peptide vaccine development for pathogenic viruses.
Fabrizio Mattei
Dr. Fabrizio Mattei graduated from University “La Sapienza” in Rome and completed his specialization in biotechnologies and oncology at the same university. In 2000, he became a fellow at the Edward Jenner Institute for Vaccine Research in David Tough's laboratory (Newbury, U.K.), where he acquired experience in the field of dendritic cell immunology. He is currently a Researcher, Group Leader and Principal Investigator at the Istituto Superiore di Sanità (Rome, Italy), where he has focused on the molecular interactions between dendritic cells and type I Interferons signalling.
His current research is aimed at understanding the role of Interferons signalling and IL-33 in the interface between tumor and immune system in both mouse and human models. Furthermore, he is also conducting research aimed at investigating on crosstalk between immune system and cancer by Cell-on-Chip devices. In addition, Dr. Mattei is developing a multidisciplinary laboratory network focused at the realization of Organ-On-Chip platforms, useful to mimic and study human diseases and cancer.
Daniel J Moore
Dr. Moore completed his undergraduate training at Harvard University where he also studied at the MGH Transplantation Biology Research Center (TBRC). He continued his focus in transplantation immunology and autoimmune disease during studies in the MSTP program at the University of Pennsylvania. He subsequently completed his training in pediatrics and pediatric endocrinology at Vanderbilt University Medical Center. His laboratory focus is on the restoration of immune regulation in individuals with autoimmune disease. He pursues this effort through studies on the cellular and molecular biology of effector and regulatory lymphocytes and their responses to tolerance-inducing immune therapies.
Héctor Manuel Mora-Montes
In 2010, I established the Laboratory of Fungal Glycobiology at Universidad de Guanajuato, Mexico, with the main goal to understand the synthesis mechanisms of the fungal cell wall and the interaction of medically relevant fungal pathogens with the host. This laboratory is characterized by its facilities to perform chemical, immunological, genetic, molecular, and cellular analyses of human fungal pathogens. Therefore, it is among a handful of research facilities within Mexico and Latin America offering a multidisciplinary and integral approach to understand the host-fungus interaction. Our group has a solid international reputation in the molecular and immunological studies of organisms belonging to the genus Candida and Sporothrix.
Karen L. Mossman
Professor of Pathology and Molecular Medicine and member of the Institute of Infectious Disease Research and McMaster Immunology Research Centre at McMaster University. Associate Editor of PLOS Pathogens and PLOS ONE and Editorial Board Member of Journal of Virology. Recipient of the 2006 Christina Fleischmann Award from the International Society for Interferon and Cytokine Research.
Barbara Nowak
Barbara is Professor at the University of Tasmania (UTAS), where she leads Aquatic Animal Health research group. Barbara has her PhD from Sydney University and has been working at UTAS since 1991. Her research interests focus on various aspects of fish health, such as fish parasitology, fish immunology and fish pathology. Barbara has published over 200 papers and supervised more than 30 PhD students. She has received awards for her research and supervision of PhD students.
Masahiro Ono
Dr Masahiro Ono was originally trained as a dermatologist, and later specialised in immunology. He obtained his PhD in 2006 by a study on regulatory T cells (Treg), and later identified the interaction of the Treg-specific transcription factor Foxp3 and the transcription factor Runx1. In 2009, he obtained a HFSP Fellowship, and joined University College London (UCL), when he established a new genomic analysis tool using a multidimensional method, Canonical Correspondence Analysis (CCA). In 2012, he was awarded a BBSRC David Phillips Fellowship, and established his lab in UCL. In 2015, he moved in the Department of Life Sciences, Imperial, and was appointed as Senior Lecturer in 2018.
Recently, the Ono group has established a novel tool for analysing temporal dynamics of cellular differentiation and activation in vivo, Timer-of-Cell-Kinetics-and-Activity (Tocky とき), and his group is using this tool to investigate mechanisms underlying T cell differentiation and T cell-mediated immune response.
Anup Singh Pathania
Dr. Anup Pathania is an Assistant Professor at the University of Nebraska Medical Center (UNMC).
His research interests include non-coding RNAs in cancer, pharmacology, and immunology. He is currently investigating the underlying mechanisms in the stabilization of PD-L1 by exosomal non-coding RNAs in neuroblastoma cells within the tumor microenvironment.
George N. Pavlakis
MD, University of Athens, Greece
PhD, Syracuse University, NY
Chief of the Human Retrovirus Section of the National Cancer Institute, USA
Interests: HIV pathogenesis, Molecular Biology, gene regulation, Biotechnology, protein engineering, cytokines, Immunotherapy, Vaccines, Nucleic acid vaccines, gene therapy
Antonella Prisco
Senior Researcher at the Institute of Genetics and Biophysics of the National Research Council.